LBRX

38.8502.97%
GS

Gad Soffer

Chief Operating & Business Officer

Mr. Gad Soffer is Chief Business Officer at LB Pharmaceuticals Inc from February 2025 having joined in February 2025 and serves as its Chief Operating Officer from March 4, 2026. He served as Chief Executive Officer at Consonance-HFW Acquisition Corp. from November 2020 to June 2021. He served as Chief Strategy Officer and Executive Vice President at Atara Biotherapeutics, Inc. since October 2016 until September 2018 and served as its Chief Operating Officer since March 2013 until October 2016. Mr. Soffer was part of the founding team at Atara Biotherapeutics, a Kleiner, Perkins, Caufield & Byers, Domain Associates-funded startup where he served initially as COO and then Chief Strategy Officer, or CSO. He was previously Chief Operating Officer at Rheos Medicines, Inc., from October 2018 to June 2020. Mr. Soffer has also served as a consultant and director of General Metabolics LLC since 2023. From 2021 to 2023, Mr. Soffer created and managed a family investment vehicle that focused on investing in the biotechnology and pharmaceutical sectors. From August 2008 to March 2013, he held various roles in Business Development and served as Global Project Leader for Abraxane at Celgene Corporation. From June 2000 to June 2001 and from April 2004 to April 2006, Mr. Soffer was a healthcare consultant with Easton Associates LLC. He also served as Director of Business Development at Celgene where he drove and supported numerous business development transactions including its strategic collaboration with Agios Pharmaceuticals and the acquisition of Abraxis Biosciences while advising on venture investment and strategic partnerships. Earlier, Mr. Soffer was a healthcare consultant with Easton Associates. He earned an MBA from Harvard Business School, an MS from Columbia University and an AB from Harvard University.

公司职务